Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting

Results Suggest CardiAMP Cell Therapy May Have Ability to Restore and Maintain Heart Function to Previously Non-Functioning Areas of the Heart Up to Two Years After Treatment

Related Keywords

Minnesota ,United States ,America ,Peter Johnston ,Peter Altman ,Yale University ,Heart Failure Society Of America ,Biocardia Inc ,American College Of Cardiology ,Site Principal Investigator At Johns Hopkins University ,Therapy Heart Failure Trial ,American College ,Assistant Professor ,Site Principal Investigator ,Johns Hopkins ,Heart Failure Society ,Minnesota Living ,Heart Failure Questionnaire ,